AU2011268450B2 - Biomarkers for the treatment of psoriasis - Google Patents

Biomarkers for the treatment of psoriasis Download PDF

Info

Publication number
AU2011268450B2
AU2011268450B2 AU2011268450A AU2011268450A AU2011268450B2 AU 2011268450 B2 AU2011268450 B2 AU 2011268450B2 AU 2011268450 A AU2011268450 A AU 2011268450A AU 2011268450 A AU2011268450 A AU 2011268450A AU 2011268450 B2 AU2011268450 B2 AU 2011268450B2
Authority
AU
Australia
Prior art keywords
level
mrna
biological sample
patient
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011268450A
Other languages
English (en)
Other versions
AU2011268450A1 (en
Inventor
Yong Lin
Peter H. Schafer
Donna Sutherland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Europe GmbH
Original Assignee
Amgen Europe GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Europe GmbH filed Critical Amgen Europe GmbH
Publication of AU2011268450A1 publication Critical patent/AU2011268450A1/en
Application granted granted Critical
Publication of AU2011268450B2 publication Critical patent/AU2011268450B2/en
Assigned to Amgen (Europe) GmbH reassignment Amgen (Europe) GmbH Request for Assignment Assignors: CELGENE CORPORATION
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2011268450A 2010-06-15 2011-06-15 Biomarkers for the treatment of psoriasis Active AU2011268450B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35511610P 2010-06-15 2010-06-15
US61/355,116 2010-06-15
US201161454916P 2011-03-21 2011-03-21
US61/454,916 2011-03-21
PCT/US2011/040430 WO2011159750A1 (fr) 2010-06-15 2011-06-15 Biomarqueurs pour le traitement du psoriasis

Publications (2)

Publication Number Publication Date
AU2011268450A1 AU2011268450A1 (en) 2012-11-22
AU2011268450B2 true AU2011268450B2 (en) 2015-07-16

Family

ID=44279738

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011268450A Active AU2011268450B2 (en) 2010-06-15 2011-06-15 Biomarkers for the treatment of psoriasis

Country Status (13)

Country Link
US (1) US20110318741A1 (fr)
EP (1) EP2583098B1 (fr)
JP (3) JP2013531499A (fr)
KR (1) KR101913868B1 (fr)
CN (1) CN103026229B (fr)
AU (1) AU2011268450B2 (fr)
BR (1) BR112012032217A2 (fr)
CA (1) CA2798742A1 (fr)
ES (1) ES2692152T3 (fr)
IL (1) IL222844A (fr)
MX (1) MX341896B (fr)
NZ (1) NZ603375A (fr)
WO (1) WO2011159750A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3281954A1 (fr) 2010-11-04 2018-02-14 Boehringer Ingelheim International GmbH Anticorps anti-il-23
EP3326649B1 (fr) 2012-05-03 2022-02-09 Boehringer Ingelheim International GmbH Anticorps anti-il-23p19
WO2014178715A1 (fr) * 2013-05-02 2014-11-06 Stichting Katholieke Universiteit Médicament personnalisé
WO2017091791A1 (fr) * 2015-11-23 2017-06-01 Sirbal Ltd. Identification de biomarqueurs dans des échantillons de sérum collectés à partir d'essais cliniques par technologie de multiplexage
WO2015173792A1 (fr) 2014-05-11 2015-11-19 Mapi Pharma Ltd. Forme amorphe d'aprémilast
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
WO2016036918A1 (fr) 2014-09-03 2016-03-10 Boehringer Ingelheim International Gmbh Composé ciblant il-23a et tnf-alpha, et ses utilisations
CN107860830A (zh) * 2017-10-10 2018-03-30 暨南大学 一种寻常型银屑病血浆中生物标志物在其靶向药物的应用
EP4182691A2 (fr) * 2020-07-17 2023-05-24 Icahn School of Medicine at Mount Sinai Biomarqueurs et classificateur du psoriasis et méthodes de traitement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234359A1 (en) * 2002-03-20 2008-09-25 Muller George W Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
WO2009120296A1 (fr) * 2008-03-24 2009-10-01 Celgene Corporation Traitement du psoriasis ou du rhumatisme psoriasique par le cyclopropyl-n-{2-{(1s)-1-(3-éthoxy-4-méthoxyphényl)-2-(méthylsulfonyl)éthyl]-3-oxoisoindoline-4-yl}carboxamide

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP1134293A3 (fr) 1992-03-04 2004-01-07 The Regents of The University of California Hybridation génomique comparative
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5605914A (en) 1993-07-02 1997-02-25 Celgene Corporation Imides
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5703098A (en) 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US6518281B2 (en) 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
US5658940A (en) 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
EP1361210B1 (fr) 1996-08-12 2008-12-24 Celgene Corporation Nouvel agent immunothérapeutique et son emploi dans la réduction de la concentration en cytokine
CA2295295A1 (fr) 1997-07-31 1999-02-11 Celgene Corporation Acides alcanohydroxamiques substitues et procede permettant de reduire le niveau de tnf-.alpha.
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6927024B2 (en) 1998-11-30 2005-08-09 Genentech, Inc. PCR assay
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US6667316B1 (en) 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7186507B2 (en) 1999-12-09 2007-03-06 Indiana University Research And Technology Corporation Fluorescent in situ RT-PCR
US6699899B1 (en) 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
AU2002247248B2 (en) 2001-03-02 2007-07-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education PCR method
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2003080048A1 (fr) 2002-03-20 2003-10-02 Celgene Corporation (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: leurs procedes d'utilisation et leurs compositions
MXPA05005161A (es) 2002-11-18 2005-07-22 Celgene Corp Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida.
CN1802353A (zh) 2002-12-30 2006-07-12 细胞基因公司 氟烷氧基取代的1,3－二氢－异吲哚化合物及其药物用途
NZ542407A (en) 2003-03-05 2008-08-29 Celgene Corp Diphenylethylene compounds and uses thereof
US6911464B2 (en) 2003-03-12 2005-06-28 Celgene Corporation N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
CA2518584A1 (fr) 2003-03-12 2004-09-23 Celgene Corporation Composes de 7-amino- isoindolyle et leurs utilisations pharmaceutiques
US7122799B2 (en) 2003-12-18 2006-10-17 Palo Alto Research Center Incorporated LED or laser enabled real-time PCR system and spectrophotometer
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US7405237B2 (en) 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
CN101389769A (zh) * 2005-12-28 2009-03-18 森托科尔公司 用于评价和治疗银屑病及相关疾病的标记与方法
US8575190B2 (en) * 2007-11-14 2013-11-05 Mitsubishi Gas Chemical Company, Inc. Method of preventing or ameliorating psoriasis using pyrroloquinoline quinone compounds
WO2009120167A1 (fr) * 2008-03-27 2009-10-01 Celgene Corporation Formes solides comprenant de la (+)-2-[1-(3-éthoxy-4-méthoxyphényl)-2-méthylsulfonyléthyl]-4-acétylaminoisoindoline-1,3-dione, leurs compositions, et utilisations associées
KR20110048536A (ko) * 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234359A1 (en) * 2002-03-20 2008-09-25 Muller George W Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
WO2009120296A1 (fr) * 2008-03-24 2009-10-01 Celgene Corporation Traitement du psoriasis ou du rhumatisme psoriasique par le cyclopropyl-n-{2-{(1s)-1-(3-éthoxy-4-méthoxyphényl)-2-(méthylsulfonyl)éthyl]-3-oxoisoindoline-4-yl}carboxamide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lowes, M. A. et al., PNAS, 2005, Vol. 102, No. 52, pages 19057- 19062 *
Malaviya, R. et al., Journal of the American Academy of Dermatology, 2006, Vol. 55, No. 4, pages 590-597 *

Also Published As

Publication number Publication date
CN103026229B (zh) 2016-03-30
KR101913868B1 (ko) 2018-12-28
CA2798742A1 (fr) 2011-12-22
IL222844A0 (en) 2012-12-31
EP2583098A1 (fr) 2013-04-24
MX341896B (es) 2016-09-07
BR112012032217A2 (pt) 2016-10-25
MX2012013803A (es) 2012-12-17
NZ603375A (en) 2014-10-31
JP2016185151A (ja) 2016-10-27
ES2692152T3 (es) 2018-11-30
CN103026229A (zh) 2013-04-03
IL222844A (en) 2016-08-31
WO2011159750A1 (fr) 2011-12-22
JP2018183146A (ja) 2018-11-22
EP2583098B1 (fr) 2018-08-08
KR20130085953A (ko) 2013-07-30
US20110318741A1 (en) 2011-12-29
JP2013531499A (ja) 2013-08-08

Similar Documents

Publication Publication Date Title
AU2011268450B2 (en) Biomarkers for the treatment of psoriasis
AU2011268450A1 (en) Biomarkers for the treatment of psoriasis
Sommer et al. Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson’s disease
Hügle et al. Tumor necrosis factor–costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts
EP2235535B1 (fr) Biomarqueurs pour prédire la sensibilité de cellules à des composés immunorégulateurs pendant un traitement de lymphome non hodgkinien
JP6573611B2 (ja) びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法
Koczan et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules
Winkler et al. The interleukin‐1 receptor–associated kinase 4 inhibitor PF‐06650833 blocks inflammation in preclinical models of rheumatic disease and in humans enrolled in a randomized clinical trial
JP2011509676A (ja) ヒトＴｈ１７細胞の選択的分化、同定および調節
US8901110B2 (en) Use of biomarkers in methods for the treatment of hepatocellular carcinoma
Gschwandtner et al. Proteome analysis identifies L1 CAM/CD 171 and DPP 4/CD 26 as novel markers of human skin mast cells
Shah et al. Behind the scenes with basophils: an emerging therapeutic target
Keenan et al. Polycomb repressive complex 2 is a critical mediator of allergic inflammation
Yuan IL-33 in autoimmunity; possible therapeutic target
Laurent et al. Interleukin‐1β–Activated Microvascular Endothelial Cells Promote DC‐SIGN–Positive Alternatively Activated Macrophages as a Mechanism of Skin Fibrosis in Systemic Sclerosis
Winkler et al. The IRAK4 kinase inhibitor PF-06650833 blocks inflammation in preclinical models of rheumatologic disease and in humans enrolled in a randomized clinical trial
Ye et al. Dysregulated interleukin 11 in primary Sjögren's syndrome contributes to apoptosis of glandular epithelial cells
JP2014517915A (ja) 多発性骨髄腫治療のためのバイオマーカー
Ulcar et al. Inhibition of prostaglandin biosynthesis in human endotoxin-stimulated peripheral blood monocytes: effects of caffeine
Stern The causes and treatment of kidney disease in scleroderma
US20150050732A1 (en) Selective differentiation, identification, and modulation of human th17 cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: AMGEN (EUROPE) GMBH

Free format text: FORMER OWNER(S): CELGENE CORPORATION